



REMARKS

Favorable reconsideration of this application in view of the remarks to follow and allowance of the claims of the present application are respectfully requested.


In the present Office Action, Claims 1 and 6 stand rejected under 35 U.S.C. §102(b) as allegedly anticipated by *Monatshefte fuer Chemie* (1997), 128 (6/7) to Shreif, et.al., and *Gazzetta Chimica Italiana* (1997), 127(12) to Elnagdi, et. al. Specifically, the Office Action avers that the top-left compound at page 690 of Shreif, et.al. and the compound 15 at page 792 of Elnagdi, et. al. fall within the formula (I) claimed in the present application. The structures of the two compounds are shown below.



In response, applicants have amended Claim 1 in a manner as indicated above. Specifically, a proviso is added in Claim 1 to exclude the two compounds. In a similar fashion, a proviso is also added in Claim 17 to exclude the two compounds. Since the amendment to Claim 1 obviates the §102(b) rejection, reconsideration and withdrawal of the instant rejection is respectfully requested.


Furthermore, Claims 1-3 and 6 stand rejected under 35 U.S.C. §102(e) as allegedly being anticipated by WO 2004/007504 to Tonani, et. al. Specifically, the Office Action avers that

Tonani, et. al. discloses a compound of the following structure which falls within formula (I) claimed in the present application.




3-(4-(4-methylpiperazin-1-yl)benzamido)-N-((R)-1-phenylethyl)-1H-thieno[2,3-c]pyrazole-5-carboxamide

In response, applicants observe that the general formula (I) disclosed in Tonani, et. al. has a structure of Thieno [3,2-c] pyrazole. In contrast, the above-mentioned compound has a structure of Thieno [2,3-c] pyrazole (the structure comparison is shown below). Therefore, such compound is not disclosed in Tonani, et. al. Moreover, since the general formula (I) of the present application has a structure of Thieno [2,3-c] pyrazole, Tonani, et. al. does not anticipate the present application. As such, reconsideration and withdrawal of the instant 102(e) rejection is respectfully requested.



general formula (I) disclosed in Tonani, et. al.



the core structure of the compound cited by the Office Action

Furthermore, Claims 1-3 and 6 stand provisionally rejected as allegedly unpatentable based on nonstatutory obviousness double patenting grounds over copending US Application No. 11/050,360 (hereinafter the '360 application).

In response, inasmuch as the '360 application is merely copending, applicants will address this provisional rejection upon the issuance of '360 application or abandonment thereof.

Furthermore, Claim 4 stands rejected under 35 U.S.C. §112, second paragraph, as allegedly failing to particularly point out and distinctly claim the subject matter. Specifically, the Office Action asserts that the expression "as defined in example 6" lacks antecedent basis.

In response, applicants have amended Claim 4 in a manner as indicated above. Specifically, applicants have incorporated 433 compounds by their chemical names from example 6 into Claim 4. The support for this amendment is found at Page 34, line 23 to page 61, line 8 of the instant specification. Since the above amendment does not introduce any new matter into the application, entry thereof is respectfully requested. Moreover, since the amendment to Claim 4 obviates the §112, second paragraph rejection, reconsideration and withdrawal of the instant rejection is respectfully requested.

Furthermore, Claims 7 and 13 stand rejected under 35 U.S.C. §112 as allegedly indefinite and under 35 U.S.C. §101 as allegedly claiming an improper definition of a process. Specifically, the Office Action asserts that both claims fail to set forth any steps involved in the process.

In response, Claim 7 is deleted without prejudice. It is to be noted that applicants have not abandoned the deleted subject matter and reserve the right to file a continuation application directed thereto. Moreover, applicants have amended Claim 13 in a manner as indicated above. Support for such amendment is found at page 31, lines 1-6 of the instant specification. Since the

above amendment does not introduce any new matter into the application, entry thereof is respectfully requested. Moreover, since the amendment to Claim 13 obviates the §112 and §101 rejections, reconsideration and withdrawal of the instant rejections are respectfully requested.

Furthermore, Claim 16 stands rejected under 35 U.S.C. §112, second paragraph, as allegedly indefinite in view of the expression “such as”.

In response, applicants have amended Claim 16 in a manner as indicated above. Specifically, applicants have deleted the term “such as methylisocyanate polystyrenic resin” in Claim 16, and have added a new Claim 18 to recite the term “methylisocyanate polystyrenic resin”. Since the above amendment does not introduce any new matter into the application, entry thereof is respectfully requested. Moreover, since the amendment to Claim 16 obviates the §112 rejection, reconsideration and withdrawal of the instant rejection is respectfully requested.

Furthermore, Claim 14 is objected to as allegedly failing to refer to Claim 1.

In response, applicants have amended Claim 14 in a manner as indicated above. Specifically, applicants have added a reference to Claim 1 in Claim 14. Therefore, reconsideration and withdrawal of the instant objection is respectfully requested.

Furthermore, Claims 8-12 stand rejected under 35 U.S.C. §112, first paragraph, as allegedly failing to comply with the enablement requirement.


In response, applicants have submitted the following biological activity data for representative compounds of the present application. The tests were carried out as described in the instant specification and the number of the compounds identified in the data correspond to the same numbers appearing in the instant specification.

Compound	Aurora-2 Inhibition IC ₅₀ (nM)	Cell Antiproliferation IC ₅₀ (nM)
421	18	184
369	22	183
408	9	71
409	3	40
411	7	133
93	203	1131
94	163	578
86	595	-

Applicants further submit that the instant specification provides sufficient description to meet the enablement requirement. Specifically, the specification (see page 1, lines 8-18) describes that malfunctioning of protein kinases (PKs) are the hallmarks of numerous diseases. For example, the enhanced activities of PKs are implicated in many malignant (i.e., cancer) and non-malignant diseases. PKs are also implicated in inflammatory conditions, in the pathogenesis and development of neurodegenerative disorders, and in the multiplication of viruses and parasites. A more detailed description of PKs malfunctioning or dysregulation can be found in *Current Opinion in Chemical Biology* 1999, 3, 459 - 465. Moreover, the specification provides detailed description of a variety of biological assay tests on the compounds claimed in the present invention (see page 22, line 24 to page 29, line 7). Furthermore, as described above, applicants have provided concrete data to show the biological activity of the claimed compounds. Therefore, in view of the above remarks, applicants submit that a person skilled in the art would readily understand that the compounds claimed in the present invention can be used in the treatment of diseases recited in Claims 8-12. As such, reconsideration and withdrawal of the instant rejection is respectfully requested.

In view of foregoing amendments and remarks, it is firmly believed that the subject application is in condition for allowance, which action is earnestly solicited.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Peter I. Bernstein', written over a horizontal line.

Peter I. Bernstein
Registration No. 43,497

Scully, Scott, Murphy & Presser, P.C.
400 Garden City Plaza-Suite 300
Garden City, New York 11530
(516) 742-4343

PIB/AZ:dg